Momenta Pharmaceuticals, Inc. (MNTA)

[MTB]

Just to be clear, I didn't say that no one else would be approved -- just not the Natco/ Mylan product referenced in the FDA response as 'clearly distinguishable from Copaxone.'

That said, I'm not aware of any others as far along as Mylan presents themselves to be, so de facto, no one else in the near or intermediate term would appear at all likely to be approved.

The genius of MNTB is their science. That's what I've been holding on for. As to the less than stellar fiscal judgment of the management, I share your opinion.

MTB